PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies ...

Please provide your email address to receive an email when new articles are posted on . At week 28, 88% of patients treated with combination therapy achieved 75% disease severity reduction vs. 47% on ...

PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, ...

DEAR MAYO CLINIC: Several years ago, I was diagnosed with lichen planus in my mouth. A dentist gave me a prescription for fluocinonide. I applied this to the lesions in my mouth but got no relief. I ...

The "Clinical Snapshot" series provides a concise examination of a clinical presentation including history, treatment, patient education, and nursing measures. Using the format here, you are invited ...

Dear Anon.: Nobody knows what causes lichen planus, an uncommon (less than 1% of people) skin condition that may also affect the mouth or vagina. It most often occurs during the ages of 30 to 60. It ...

Please provide your email address to receive an email when new articles are posted on . All patients treated with baracitinib for lichen planus had a response at week 12. After 1 week of treatment, 37 ...

A survey of US dermatologists revealed low screening rates for common comorbidities in patients with lichen planus (LP), with significant reliance on topical treatments. An anonymous survey with ...

Lipella Pharmaceuticals Inc. announced that the FDA has approved an Expanded Access Program for LP-310, an oral rinse formulated to treat oral lichen planus (OLP), a debilitating condition affecting ...

Oral lichen planus (OLP) is a chronic, immune‐mediated mucosal disorder characterised by a range of clinical presentations, from asymptomatic reticular patterns to painful erosive lesions. The ...